{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:42:30Z","timestamp":1795059750811,"version":"4.10.2"},"reference-count":33,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,27]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Malignant histiocytoses (MH) are rare and poorly understood cancers, with no established therapeutic guidelines. We conducted a national retrospective study of MH diagnosed in France between 2000 and 2023. All cases underwent centralized histological review, and several malignant tumors with a stroma highly enriched in histiocytes were excluded. In total, 141 patients were included, with a median age of 62 years (range, 1-87). The cases comprised either primary MH (64%) or MH associated with other hematologic malignancies (36%). Phenotypes corresponded to histiocytic (43%), interdigitating dendritic cell (37%) or Langerhans cell (12%) sarcomas, or high-grade indeterminate dendritic cell tumors (10%), as per the World Health Organization classification. Tumor cells were almost universally positive for CSF1R and PU.1, and 85% showed phosphorylated extracellular signal\u2013regulated kinase positivity. Next-generation sequencing was performed in 75 cases. Mutations in the MAPK pathway were more frequent in secondary compared with primary MH (90% vs 55%; P = .0012). PTPN11 mutations were exclusively observed in primary MH (P = .0035). Mutations in genes related to DNA methylation mechanisms (TET2, ASXL1, DNMT3A) and TP53 were present in 20% and 14% of cases, respectively. Although therapeutic regimens varied considerably, our results demonstrate that surgical resection in localized cases, and the use of BRAF or MEK inhibitors achieved the highest complete response rates, at 63% and 21%, respectively. The prognosis remains poor, with a 5-year overall survival rate of 31%, which is comparable to that of T\/natural killer cell lymphomas. Prospective follow-up and a standardized treatment approach in specialized reference centers are crucial to improving patient survival. This trial was registered at www.clinicaltrials.gov as #NCT04437381.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015208","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T20:05:46Z","timestamp":1740600346000},"page":"2530-2541","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":24,"title":["Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France"],"prefix":"10.1182","volume":"9","author":[{"given":"Camille","family":"Bigenwald","sequence":"first","affiliation":[{"name":"1D\u00e9partement d\u2019H\u00e9matologie, Gustave Roussy, Villejuif, France"},{"name":"2INSERM U1015, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7767-755X","authenticated-orcid":false,"given":"Damien","family":"Roos-Weil","sequence":"additional","affiliation":[{"name":"3Sorbonne Universit\u00e9, Hematology Unit, Centre Hospitalier Universitaire Piti\u00e9-Salp\u00eatri\u00e8re, Assistance Publique H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2337-8693","authenticated-orcid":false,"given":"Arnaud","family":"Pag\u00e8s","sequence":"additional","affiliation":[{"name":"4Bureau de Biostatistique et d'Epid\u00e9miologie, Gustave Roussy et Centre de Recherche en Epid\u00e9miologie et Sant\u00e9 des Populations U1018, Oncostat, labellis\u00e9 Ligue Contre le Cancer, INSERM, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"H\u00e9lias-Rodzewicz","sequence":"additional","affiliation":[{"name":"5Paris-Saclay University, Versailles Saint Quentin en Yvelynes University, EA4340-Biomarqueurs et Essais Cliniques en Canc\u00e9rologie et Onco-H\u00e9matologie, Assistance Publique H\u00f4pitaux de Paris, Ambroise-Par\u00e9 Hospital, Smart Imaging, Service de Pathologie, Boulogne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Copie-Bergman","sequence":"additional","affiliation":[{"name":"6Paris-Est Cr\u00e9teil University, INSERM, Institut Mondor de Recherche Biom\u00e9dicale, Pathology Department, Assistance Publique des H\u00f4pitaux de Paris, Centre Hospitalier Universitaire Henri Mondor, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0512-9666","authenticated-orcid":false,"given":"Marzieh","family":"Nashvi","sequence":"additional","affiliation":[{"name":"2INSERM U1015, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2422-2121","authenticated-orcid":false,"given":"Pierre","family":"Khneisser","sequence":"additional","affiliation":[{"name":"7Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4335-4138","authenticated-orcid":false,"given":"Marie","family":"Parrens","sequence":"additional","affiliation":[{"name":"8Pathology Department, University of Bordeaux, Haut-L\u00e9v\u00eaque Hospital, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Traverse-Glehen","sequence":"additional","affiliation":[{"name":"9Unit\u00e9 de Formation et de Recherche Claude Bernard Lyon 1, Hospices Civils de Lyon, Institut de Pathologie Multisite, H\u00f4pital Lyon Sud, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-8306","authenticated-orcid":false,"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[{"name":"10Universit\u00e9 Claude Bernard Lyon 1, Hesper Laboratory, Department of Medical Oncology, Centre Leon Berard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Ysebaert","sequence":"additional","affiliation":[{"name":"11Hematology Department, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-2169","authenticated-orcid":false,"given":"Tony","family":"Marchand","sequence":"additional","affiliation":[{"name":"12Service d'H\u00e9matologie Clinique, Centre Hospitalier Universitaire de Rennes, Universit\u00e9de Rennes, Unit\u00e9 Mixte de Recherche 1236, INSERM, \u00c9tablissement Fran\u00e7ais du Sang Bretagne, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Razanamahery","sequence":"additional","affiliation":[{"name":"13Department of internal medicine and clinical immunology, Dijon University Hospital, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Charlotte","sequence":"additional","affiliation":[{"name":"14Pathology Department, Piti\u00e9 Salp\u00eatri\u00e8re, Assistance Publique H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7707-5794","authenticated-orcid":false,"given":"Antoine","family":"Neel","sequence":"additional","affiliation":[{"name":"15Service de M\u00e9decine Interne, Centre Hospitalier Universitaire de Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4689-3882","authenticated-orcid":false,"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[{"name":"16Institut d\u2019H\u00e9matologie, Centre Hospitalier Universitaire de Caen, Universit\u00e9 de Caen-Normandie, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1135-0351","authenticated-orcid":false,"given":"J\u00e9r\u00e9mie","family":"Dion","sequence":"additional","affiliation":[{"name":"17Internal Medicine and Immunopathology Department, University Hospital Center of Toulouse Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve-Marie","family":"Nazal-Traissac","sequence":"additional","affiliation":[{"name":"18Service de M\u00e9decine Interne, Centre Hospitalier Agen-N\u00e9rac, Agen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Tardy","sequence":"additional","affiliation":[{"name":"19Departement d'H\u00e9matologie, Centre Hospitalier Annecy Genevois, Annecy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Salmeron","sequence":"additional","affiliation":[{"name":"20D\u00e9partement d\u2019H\u00e9matologie, Centre Hospitalier Intercommunal de Poissy, Saint Germain en Laye, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Monjanel","sequence":"additional","affiliation":[{"name":"21Service de M\u00e9decine Interne, Centre Hospitalier Henri Mondor d'Aurillac, Aurillac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Idbaih","sequence":"additional","affiliation":[{"name":"22Sorbonne Universit\u00e9, INSERM, Centre National de la Recherche Scientifique, Unit\u00e9 Mixte de Recherche S 1127, Institut du Cerveau et de la Moelle \u00c9pini\u00e8re, Institut du Cerveau et de la Moelle, Assistance Publique H\u00f4pitaux de Paris, H\u00f4pitaux Universitaires La Piti\u00e9 Salp\u00eatri\u00e8re Charles Foix, Service de Neurologie 2-Mazarin, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0384-6370","authenticated-orcid":false,"given":"S\u00e9bastien","family":"H\u00e9ritier","sequence":"additional","affiliation":[{"name":"23French Reference Center for Histiocytosis, Department of Pediatric Hematology and Oncology, Trousseau Hospital, Assistance Publique H\u00f4pitaux de Paris, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Haroche","sequence":"additional","affiliation":[{"name":"24Sorbonne University, Internal Medicine Department 2, Institut E3M, French Reference Centre for Histiocytosis, Piti\u00e9-Salp\u0207tri\u00e8re Hospital, Centre d'Immunologie et des Maladie Infectieuses INSERM-UMRS 1135, Assistance Publique H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4485-146X","authenticated-orcid":false,"given":"Jean","family":"Donadieu","sequence":"additional","affiliation":[{"name":"23French Reference Center for Histiocytosis, Department of Pediatric Hematology and Oncology, Trousseau Hospital, Assistance Publique H\u00f4pitaux de Paris, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6073-4466","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Emile","sequence":"additional","affiliation":[{"name":"5Paris-Saclay University, Versailles Saint Quentin en Yvelynes University, EA4340-Biomarqueurs et Essais Cliniques en Canc\u00e9rologie et Onco-H\u00e9matologie, Assistance Publique H\u00f4pitaux de Paris, Ambroise-Par\u00e9 Hospital, Smart Imaging, Service de Pathologie, Boulogne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"5966","key":"2025052708520378700_bib1","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1126\/science.1178331","article-title":"Development of monocytes, macrophages, and dendritic cells","volume":"327","author":"Geissmann","year":"2010","journal-title":"Science"},{"issue":"1","key":"2025052708520378700_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.immuni.2014.06.013","article-title":"Origin and functions of tissue macrophages","volume":"41","author":"Epelman","year":"2014","journal-title":"Immunity"},{"issue":"23","key":"2025052708520378700_bib3","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1016\/j.cell.2022.10.007","article-title":"Macrophages in health and disease","volume":"185","author":"Park","year":"2022","journal-title":"Cell"},{"issue":"1","key":"2025052708520378700_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.0105-2896.2009.00879.x","article-title":"Origin and development of dendritic cells","volume":"234","author":"Liu","year":"2010","journal-title":"Immunol Rev"},{"key":"2025052708520378700_bib5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev-immunol-020711-074950","article-title":"The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting","volume":"31","author":"Merad","year":"2013","journal-title":"Annu Rev Immunol"},{"issue":"22","key":"2025052708520378700_bib6","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2025052708520378700_bib7","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2025052708520378700_bib8","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"2025052708520378700_bib9","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1182\/blood-2007-11-124792","article-title":"Clonally related follicular lymphomas and histiocytic\/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone","volume":"111","author":"Feldman","year":"2008","journal-title":"Blood"},{"issue":"suppl 1","key":"2025052708520378700_bib10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s12288-014-0375-3","article-title":"Histiocytic sarcoma with acute lymphoblastic leukemia a rare association: case report and literature review","volume":"30","author":"Ganapule","year":"2014","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"6","key":"2025052708520378700_bib11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/PAS.0b013e31819287b8","article-title":"High frequency of clonal immunoglobulin receptor gene rearrangements in sporadic histiocytic\/dendritic cell sarcomas","volume":"33","author":"Chen","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2025052708520378700_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s12308-024-00603-9","article-title":"Misdiagnosis of Hodgkin disease as histiocytosis is associated with adverse consequences","volume":"17","author":"Emile","year":"2024","journal-title":"J Hematop"},{"issue":"10295","key":"2025052708520378700_bib13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(21)00311-1","article-title":"Histiocytosis","volume":"398","author":"Emile","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"2025052708520378700_bib14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/ajh.27263","article-title":"Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis","volume":"99","author":"Ruan","year":"2024","journal-title":"Am J Hematol"},{"issue":"10","key":"2025052708520378700_bib15","doi-asserted-by":"crossref","first-page":"100268","DOI":"10.1016\/j.modpat.2023.100268","article-title":"Malignant histiocytosis comprises a phenotypic spectrum that parallels the lineage differentiation of monocytes, macrophages, dendritic cells, and Langerhans cells","volume":"36","author":"Ravindran","year":"2023","journal-title":"Mod Pathol"},{"issue":"4","key":"2025052708520378700_bib16","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3324\/haematol.2019.230375","article-title":"Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups","volume":"105","author":"Egan","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"2025052708520378700_bib17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41379-020-00673-x","article-title":"The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy","volume":"34","author":"Egan","year":"2021","journal-title":"Mod Pathol"},{"issue":"6","key":"2025052708520378700_bib18","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41379-018-0200-x","article-title":"Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma","volume":"32","author":"Shanmugam","year":"2019","journal-title":"Mod Pathol"},{"issue":"11","key":"2025052708520378700_bib19","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/00000478-199811000-00009","article-title":"True histiocytic lymphoma: a morphologic, immunohistochemical, and molecular genetic study of 13 cases","volume":"22","author":"Copie-Bergman","year":"1998","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"2025052708520378700_bib20","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/ajh.26938","article-title":"Molecular and clinicopathologic characterization of pediatric histiocytoses","volume":"98","author":"H\u00e9lias-Rodzewicz","year":"2023","journal-title":"Am J Hematol"},{"issue":"2","key":"2025052708520378700_bib21","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/his.14909","article-title":"PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte-rich tumours","volume":"83","author":"Ungureanu","year":"2023","journal-title":"Histopathology"},{"issue":"5","key":"2025052708520378700_bib22","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1002\/ajh.26119","article-title":"Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis","volume":"96","author":"Goyal","year":"2021","journal-title":"Am J Hematol"},{"issue":"16","key":"2025052708520378700_bib23","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1182\/blood-2010-02-246140","article-title":"Beyond hairy cell: the activity of cladribine in other hematologic malignancies","volume":"116","author":"Sigal","year":"2010","journal-title":"Blood"},{"issue":"7749","key":"2025052708520378700_bib24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"issue":"31","key":"2025052708520378700_bib25","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.19.00456","article-title":"Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study","volume":"37","author":"Donadieu","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025052708520378700_bib26","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41375-024-02459-5","article-title":"The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms","volume":"39","author":"Salmon-Divon","year":"2025","journal-title":"Leukemia"},{"issue":"16","key":"2025052708520378700_bib27","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","article-title":"Pexidartinib: first approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"issue":"10","key":"2025052708520378700_bib28","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2217\/fon-2023-0238","article-title":"The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor","volume":"20","author":"Tap","year":"2024","journal-title":"Future Oncol"},{"issue":"10","key":"2025052708520378700_bib29","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.22.00958","article-title":"Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I\/II study","volume":"41","author":"Kitko","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025052708520378700_bib30","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","article-title":"Axatilimab in recurrent or refractory chronic graft-versus-host disease","volume":"391","author":"Wolff","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"2025052708520378700_bib31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3892\/mco.2022.2569","article-title":"Application of PD-L1 blockade in refractory histiocytic sarcoma: a case report","volume":"17","author":"Imataki","year":"2022","journal-title":"Mol Clin Oncol"},{"issue":"3","key":"2025052708520378700_bib32","doi-asserted-by":"crossref","first-page":"e13741","DOI":"10.1111\/crj.13741","article-title":"Primary pulmonary histiocytic sarcoma with high PD-L1 expression benefited from immunotherapy: a case report and bioinformatic analysis","volume":"18","author":"Lin","year":"2024","journal-title":"Clin Respir J"},{"issue":"9","key":"2025052708520378700_bib33","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.3324\/haematol.2022.280948","article-title":"Prolonged remission with pembrolizumab and radiation therapy in a patient with multisystem Langerhans cell sarcoma","volume":"107","author":"Zanwar","year":"2022","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2530\/2375072\/blooda_adv-2024-015208-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2530\/2375072\/blooda_adv-2024-015208-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T12:52:13Z","timestamp":1748350333000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/10\/2530\/535782\/Characterization-and-treatment-outcomes-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,5,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015208","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,27]]},"published":{"date-parts":[[2025,5,19]]}}}